10 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
European HIV Vaccine Alliance (EHVA): a EU platform for the discovery and evaluation of novel prophylactic and therapeutic vaccine candidates (EHVA)
Date du début: 1 janv. 2016, Date de fin: 31 déc. 2020,
Many HIV vaccine concepts and several efficacy trials have been conducted in the prophylactic and therapeutic fields with limited success. There is an urgent need to develop better vaccines and tools predictive of immunogenicity and of correlates of protection at early stage of vaccine development to mitigate the risks of failure. To address these complex and challenging scientific issues, the Eur ...
Voir le projet
43
Participants partenaires
TERMINÉ
Standardization and Development of Assays for Assessment of Influenza Vaccines Correlates of Protection (FLUCOP)
Date du début: 1 mars 2015, Date de fin: 29 févr. 2020,
Background: Influenza viruses cause annual epidemic and occasional pandemics, both of which induce significant morbidity and mortality. Influenza infections affect all age groups but children and adults over the age of 65 are at most risk of developing severe disease.Vaccination is the most effective approach to reduce the impact of annual influenza outbreaks and potential pandemics, however, the ...
Voir le projet
26
Participants partenaires
TERMINÉ
Accelerated Development of Vaccine benefit-risk Collaboration in Europe (ADVANCE)
Date du début: 1 oct. 2013, Date de fin: 30 sept. 2018,
Aim: The ADVANCE vision is focused on Timely and Best Evidence on Vaccine Effects. Our mission is to establish a best practice framework to rapidly provide robust data on vaccine benefits and risks to support accelerated decision-making.Approach: To achieve this vision through a public-private partnership, ADVANCE partners 1. establish common grounds and rules for collaboration between public and ...
Voir le projet
30
Participants partenaires
TERMINÉ
Model-based preclinical development of anti-tuberculosis drug combinations (PREDICT-TB)
Date du début: 1 mai 2012, Date de fin: 30 oct. 2017,
Drug development in TB requires new integrated methods to transition the novel combination regimens needed to shorten first-line therapy and combat multi-drug resistance. Although new agents are emerging, the path to registration of such regimens remains uncertain while capacity for pivotal trials is limited. Selection and optimization of drug combinations for development depends on preclinical sy ...
Voir le projet
23
Participants partenaires
TERMINÉ
Vaccination against Shigella and ETEC: novel antigens, novel approaches (STOPENTERICS)
Date du début: 1 nov. 2010, Date de fin: 30 avr. 2017,
To contribute to the development of vaccines against Shigella and ETEC for children of the developing world, STOPENTERICS will provide novel solutions by imposing a two-fold paradigm switch: (i) to break the dogma of serotype-specificity by inducing a cross-protective immunity (ii) to improve the immunogenicity of Shigella glycoconjugates by using synthetic oligosacharides mimicking the lipopolysa ...
Voir le projet
20
Participants partenaires
TERMINÉ
Biomarkers For Enhanced Vaccine Safety (BIOVACSAFE)
Date du début: 1 mars 2012, Date de fin: 31 déc. 2016,
BioVacSafe is a concise consortium of selected academic, public, and SME participants used to co-working in industry-led projects, organised into focused Activity Cores to generate knowledge and tools to benchmark licensed vaccine reactogenicity, and create practical and generalizable guidelines and techniques to enhance immunosafety of novel vaccines from pre-development to post-marketing surveil ...
Voir le projet
24
Participants partenaires
TERMINÉ
Infection biology training network: shaping the future of infectious diseases treatments (INBIONET)
Date du début: 1 janv. 2013, Date de fin: 31 déc. 2016,
...s internationally recognized in the fields of microbial pathogenesis, innate immunity and molecular recognition, an intensive research SME, Preclin Biosystems, a multinational pharmaceutical company, Sanofi-Aventis, and a technological park (ParcBit). INBIONET partners will embark on the analysis of bacteria, viruses and enteric parasites specified by various infection strategies to identify cellu ...
Voir le projet
11
Participants partenaires
TERMINÉ
More Medicines for Tuberculosis (MM4TB)
Date du début: 1 févr. 2011, Date de fin: 31 juil. 2016,
The More Medicines for Tuberculosis (MM4TB) consortium evolved from the highly successful FP6 project, New Medicines for TB (NM4TB), that delivered a candidate drug for clinical development two years ahead of schedule. Building on these firm foundations and exploiting its proprietary pharmacophores, MM4TB will continue to develop new drugs for TB treatment. An integrated approach will be impleme ...
Voir le projet
27
Participants partenaires
TERMINÉ
Pharmaceutical Medicine Training Programme (PHARMATRAIN)
Date du début: 1 mai 2009, Date de fin: 30 avr. 2014,
"The proposed Pharmaceutical Medicine Training Programme provides a comprehensive solution for the complex needs of integrated drug development for all professionals involved, incl. physicians, pharmaceutical scientists,biologists, biometricians, health economists, and safety and regulatory scientists from universities, regulatory agencies, large, middle-sized and small pharmaceutical enterprises, ...
Voir le projet
52
Participants partenaires
TERMINÉ
EUROpean consortium on NEUTralising antibodies using gp41 (EURONEUT-41)
Date du début: 1 janv. 2008, Date de fin: 31 mars 2014,
There is now an increasingly solid body of scientific evidence which demonstrates that the binding of small molecular weight compounds, peptides and antibodies (Abs) to fusion-intermediate conformations of gp41 leads to an inhibition of HIV cell entry. The principal aim of this project is to exploit this information by establishing a platform where gp41-derived vaccine candidates will be designed ...
Voir le projet